SCHEMBL20873229

SCHEMBL20873229

CCOc1ccc(P(c2ccc(OCC)cc2)c2ccccc2P(c2cccc(OCC)c2)c2cccc(OCC)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.47
TP53 P04637 2/20 0.45
CYP3A4 P08684 1/20 0.45
NQO1 P15559 1/20 0.44
MAPK1 P28482 5/20 0.43
LMNA P02545 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
RELA Q04206 1/20 0.40
MAPT P10636 4/20 0.39
MEN1 O00255 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 2/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 2/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6678264 0.85 CYP3A4 (0.52) LTA4HTP53CYP3A4NQO1MAPK1
SCHEMBL10881069 0.83 TP53 (0.57) LTA4HTP53CYP3A4NQO1MAPK1
SCHEMBL6680067 0.79 LTA4H (0.61) LTA4HTP53CYP3A4NQO1L3MBTL1
SCHEMBL19553639 0.78 LTA4H (0.51) LTA4HTP53NQO1MAPK1LMNA
SCHEMBL21111863 0.76 DRD1 (0.69) LTA4HTP53CYP3A4MAPK1LMNA
SCHEMBL431054 0.75 NQO1 (0.70) LTA4HNQO1RELAMAPTTDP1
SCHEMBL20873235 0.74 ACHE (0.47) CYP3A4RELASMN1; SMN2ALDH1A1CYP1A2
SCHEMBL2155506 0.73 TP53 (0.53) LTA4HTP53CYP3A4NQO1MAPK1
SCHEMBL2153438 0.73 TP53 (0.53) LTA4HTP53CYP3A4NQO1MAPK1
SCHEMBL21111887 0.73 DRD1 (0.72) LTA4HTP53CYP3A4NQO1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3466988-B1 OLIGOMERIZING CATALYST AND METHOD FOR PREPARING ETHYLENE OLIGOMER USING SAME SK INNOVATION CO LTD (KR) 2023-11-29 EP disclosed
US-11235315-B2 Oligomerization catalyst and method for preparing ethylene oligomer using same SK INNOVATION CO., LTD. (KR) 2022-02-01 US disclosed
US-20190308178-A1 Oligomerization Catalyst and Method for Preparing Ethylene Oligomer Using Same SK INNOVATION CO, LTD. (KR) 2019-10-10 US disclosed
EP-3466988-A1 OLIGOMERIZING CATALYST AND METHOD FOR PREPARING ETHYLENE OLIGOMER USING SAME SK Innovation Co., Ltd. (KR) 2019-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11235315-B2 Oligomerization catalyst and method for preparing ethylene oligomer using same AP1M1, NOD2, NOD1 LTA4H 1421/4885TP53 1915/4885CYP3A4 1114/4885
US-20190308178-A1 Oligomerization Catalyst and Method for Preparing Ethylene Oligomer Using Same AP1M1, NOD2, NOD1 LTA4H 1384/4885TP53 1975/4885CYP3A4 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.